为不断提高公司管理效率，保证公司合规运作，现对《公司章程》部分条款 予以修订，具体如下： | | 修订前 | 修订后 | | --- | --- | --- | | 第一百一十八条 | 董事长行使下列职 | 第一百一十八条 董事长行使下列职 | | 权： | | 权： | | （一）主持股东会和召集、主持董 | | （一）主持股东会和召集、主持董 | | 事会会议； | | 事会会议； | | （二）督促、检查董事会决议的执 | | （二）督促、检查董事会决议的执 | | 行； | | 行； | | （三）依法行使法定代表人的职 | | （三）依法行使法定代表人的职 | | 权； | | 权； | | （四）董事会授予的其他职权。 | | （四）董事会秘书由董事长提名， | | | | 同时董事长可以决定公司副总经理、财 | | | | 务总监提名人选； | | | | （五）对于无需公司董事会决定聘 | | | | 任或者解聘以外的负责管理人员，总监 | | | | 级别以上的管理层由董事长决定聘任 | | | | 或者解聘。 | | | | （六）三博脑科按出资比例向子公 | | | | 司委派或推荐董事 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-045 三博脑科医院管理集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 11 月 06 日 7、出席对象： （1）于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体已发行有表 决权股份的股东均有权出席股东会，并可以以书面形式委托代理人出席会议和参加表决， 该股东代理人不必是本公司股东； 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 12 日 15:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票 ...

三博脑科医院管理集团股份有限公司 2025 年第三季度报告 证券代码：301293 证券简称：三博脑科 公告编号：2025-042 三博脑科医院管理集团股份有限公司 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 1 三博脑科医院管理集团股份有限公司 2025 年第三季度报告 一、主要财务数据 2025 年第三季度报告 （一） 主要会计数据和财务指标 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 445,991,649.75 | 25.65% | 1,273,244,0 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-041 三博脑科医院管理集团股份有限公司 第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 三博脑科医院管理集团股份有限公司（以下简称"公司"）第三届董事会第十 五次会议于 2025 年 10 月 27 日在公司会议室以现场结合通讯的方式召开。会议 通知于 2025 年 10 月 21 日以电子邮件等方式发出。本次会议应出席董事 9 名， 实际出席的董事 9 人，会议由董事长张阳先生主持，公司高级管理人员列席了会 议。本次会议的召集、召开和表决程序符合《公司法》等法律法规和《公司章程》 的有关规定。 经与会董事认真审议，会议形成了如下决议： （一）审议通过《2025 年第三季度报告》 经审议，公司董事会认为：公司 2025 年第三季度报告的编制符合相关法律 法规及《公司章程》的有关规定，报告真实、准确、完整地反映了公司 2025 年 第三季度的财务状况和经营情况，不存在虚假记载、误导性陈述或重大遗漏。 表决结果：9 票同意，0 票反对，0 票 ...

三博脑科公告，第三季度营收为4.46亿元，同比增长25.65%；净利润为1393.25万元，同比下降 63.26%。前三季度营收为12.73亿元，同比增长20.26%；净利润为8362.82万元，同比下降20.01%。 ...

Core Viewpoint - The article discusses the comprehensive deployment of China's 15th Five-Year Plan, emphasizing the development of a modern industrial system, a strong domestic market, and coordinated regional development, with a particular focus on emerging industries like brain-machine interfaces [2][3][4]. Industry Development - The 15th Five-Year Plan aims to cultivate new pillar industries, with a focus on future industries such as quantum technology, bio-manufacturing, hydrogen energy, nuclear fusion, brain-machine interfaces, embodied intelligence, and 6G mobile communication [3][4]. - Brain-machine interface technology is highlighted for its potential to transform economic structures and improve societal welfare, enabling applications in medical rehabilitation, industrial manufacturing, and consumer electronics [3][4]. Policy Support - The brain-machine interface has been officially recognized as a future industry by the Ministry of Industry and Information Technology and other departments, marking its entry into national strategic planning [4][5]. - The "Implementation Opinions" released in July 2025 set clear goals for the brain-machine interface industry, aiming for breakthroughs in core technologies by 2027 and positioning the industry among the world's leaders by 2030 [4][5]. Market Potential - The brain-machine interface industry is projected to create a market scale in the hundreds of billions, generating numerous high-skilled job opportunities and establishing a new competitive advantage for China in global technology [6][7]. - The industry is expected to evolve towards more precise, safer, and more accessible technologies during the 15th Five-Year Plan, with significant advancements in hardware and software capabilities [6][7]. Commercial Applications - Companies are actively engaging in the brain-machine interface space, with various business models targeting both B2B and B2C markets, including medical rehabilitation and consumer electronics [7][8]. - Examples of commercial initiatives include partnerships for developing implantable systems, clinical transformation centers, and innovative products like brain-controlled games and smart mattresses [7][8]. Conclusion - The emphasis on brain-machine interfaces in the 15th Five-Year Plan signifies a shift from following to leading in this technology, aligning with China's development philosophy centered on improving human welfare [8].

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]

全球专家齐聚，共话癫痫外科新篇章 大会开幕式由首都医科大学三博脑科医院科研处处长王雄飞教授主持，首都医科大学校长、中国医学科 学院院长吉训明院士，中国抗癫痫协会创会会长李世绰教授，现任会长周东教授，IESS主席Christian Dorfer教授，以及首都医科大学三博脑科医院首席专家栾国明教授等嘉宾出席并致辞。 与会专家一致认为，癫痫外科已进入精准化、微创化、智能化的全新阶段，中国在脑科学研究领域的国 家战略支持为全球癫痫治疗提供了创新生态与临床转化平台。 吉训明院士在致辞中指出，癫痫仍是现代医学最具挑战性的难题之一，其治疗需要全球科学家的共同探 索。中国已将脑科学列为关键前沿领域，通过大规模计划加速大脑机制研究，这种国家层面的投入正推 动人才、资源与技术的深度融合。本次大会不仅是学术交流的舞台，更是全球协作的重要契机，"真正 的进步需要彻底的合作，包括分享成功经验与失败教训，以透明度激发临床突破的火花"。 抗癫痫仍然是全球健康领域最重大的挑战之一。李世绰教授以全球5000万癫痫患者的生存现状为切入 点，揭示了诊疗体系的短板："数百万患者无法获得及时手术，太多家庭在沉默中承受负担。"他肯定了 近年来癫痫外科的 ...

Core Viewpoint - The medical services sector experienced a decline of 2.76% on October 17, with Sanbo Brain Science leading the drop. The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1]. Summary by Category Market Performance - The medical services sector saw significant declines, with Sanbo Brain Science falling by 7.13% to a closing price of 58.96. Other notable declines included He Yuan Biological (-5.26%), Jiu Zhou Pharmaceutical (-4.70%), and Xin Li Cheng (-4.49%) [2]. - In contrast, Hai Te Biological and Cheng Da Pharmaceutical were among the few gainers, with increases of 6.23% and 3.15%, respectively [1][2]. Trading Volume and Value - The trading volume for Hai Te Biological reached 232,100 shares with a transaction value of 850 million yuan, while Cheng Da Pharmaceutical had a volume of 61,000 shares and a value of 200 million yuan [1]. - The overall medical services sector saw a net outflow of 1.181 billion yuan from major funds, while retail investors contributed a net inflow of 939 million yuan [2]. Fund Flow Analysis - Major funds showed a net inflow of 171 million yuan into Aier Eye Hospital, while other companies like Hai Te Biological and Cheng Da Pharmaceutical experienced mixed fund flows [3]. - Retail investors showed a significant net inflow into several stocks, indicating a potential shift in market sentiment despite the overall sector decline [3].

Core Viewpoint - The company, Sanbo Neuroscience, has confirmed that it has conducted one interventional brain-machine interface surgery at its Fujian facility, utilizing polyethylene glycol products, but specific product details are confidential due to collaboration agreements [1] Group 1 - The company has only performed one brain-machine interface surgery to date [1] - The surgery involved the use of polyethylene glycol, which meets national standards [1] - The specific product information used in the surgery is considered confidential among the collaborating parties [1]